MOLN | Molecular Partners AG Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	5.31 - 5.31
52 Week Range	3.32 - 12.70
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	2,450
Average Volume	25,011
Shares Outstanding	36,863,100
Market Cap	195,743,061
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-06-16

Valuation
Profitability
Growth
Health
P/E Ratio	-2.53
Forward P/E Ratio	N/A
EPS	-2.10
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	167
Country	Switzerland
Website	MOLN

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

MOLN's peers: ADAG, ANTX, ALZN, ANEB, ANIX, APLT, ATAI, AVTX, NTRB, PMCB, CADL, CELC, CLGN, CLNN, CSBR, DBVT, DYAI, FENC, FHTX, GANX, GHRS, GLTO, GNFT, GNTA, HCWB, HOWL, IMNM, CYBN, IPHA, JANX, DRTS, MGNX, MNMD, MNOV, MNPR, MLYS, PHVS, PEPG, CYT, RZLT, ELYM, PMVP, EWTX, RLYB, OPT, GLUE, TRDA, VIGL, NAUT, NLSP, OLMA, ORIC, PHAR, PRAX, PRLD, PRTC, PSTX, RANI, RAPT, SEER, ACRV, SLDB, TYRA, XLO, BLTE, HLVX, QNCX, NAMS, ZVRA

*Chart delayed

Analyzing fundamentals for MOLN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see MOLN Fundamentals page.

Watching at MOLN technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on MOLN Technicals page.